Yellow dye laser thermotherapy of choroidal neovascularisation in age related macular degeneration

Margo R Beintema, Jendo A Oosterhuis, Fred Hendrikse

Abstract

Aim—A pilot study of the feasibility of using dye laser thermotherapy (LTT) at a subcoagulation temperature to occlude newly formed vessels in patients with age related macular degeneration (AMD).

Methods—Choroidal neovascularisation (CNV) in 24 eyes with exudative AMD was treated with a continuous wave yellow laser at 578 nm. Parameters were an exposure time of 2 or 5 seconds, a spot size of 750 or 1000 µm, and a laser power of 100–200 mW. The clinical end point was a greyish discoloration at the treatment site. The effect of thermotherapy was documented by ophthalmoscopic and fluorescein angiographic examination. The follow up after LTT was 4–16 months, mean 5 months.

Results—LTT resulted in total occlusion of newly formed vessels in 15 eyes (62.5%). Neovascular outgrowth within 6 weeks and recurrences 2–4 months after LTT were observed, each in three eyes. In six of the nine eyes with occlusion of CNV without recurrence the choriocapillaris remained perfused; in two eyes only the large choroidal vessels remained perfused. In six eyes pigmentary changes were the only ophthalmoscopic and fluorescein angiographic signs of treatment. The effect of LTT is rather unpredictable.

Conclusion—CNV in AMD can effectively be treated by yellow dye laser thermotherapy with preservation of choroidal perfusion. The technique requires dosimetric adaptation.

(Br J Ophthalmol 2001;85:708–713)

Laser photoocoagulation is a common treatment for choroidal neovascularisation (CNV) secondary to age related macular degeneration (AMD). Newly formed vessels become occluded at coagulation temperatures of 65°C and higher. Both retina and choroid in the treated area become necrotic and develop into an atrophic or fibrotic scar. Blood vessels can also be occluded by transpupillary laser thermotherapy (LTT) at lower, subcoagulation temperatures of 45–60°C, as is evident from studies of transpupillary LTT of choroidal melanomas. Temperatures in this range cause necrosis of both tumour cells and endothelial cells mediated by nuclear pyknosis and mitochondrial damage, which block cell metabolism.

This pilot study investigated whether yellow dye laser thermotherapy can be used to cause selective occlusion of newly formed vessels in AMD with sparing of the sensory retina and maintenance of choroidal perfusion.

Material and methods

LTT was performed in 24 eyes of 24 patients with AMD and fluorescein angiographic evidence of CNV in the macula. All eyes had the classic type of CNV; in three eyes it was combined with an occult component with late leakage of an undetermined but well demarcated source in the early phase. All patients had a general ophthalmological examination before treatment, which included measurement of best corrected Snellen visual acuity, slit lamp and fluorescein angiographic examination. Ophthalmological data are summarised in Table 1. Visual complaints existed for 1–20 weeks; in 14 patients they existed for 6 weeks or longer. Twenty eyes had a visual acuity of 1/60 to 0.16 and four eyes an acuity of 0.2 to 0.4. In 13 eyes the CNV also affected the subfoveal area. Eyes were included that had the classic type of CNV or with both the occult and the classic type of CNV, when the area of the occult CNV did not exceed half of the total CNV affected area. Fifteen eyes showed subretinal haemorrhages, partly obscuring the neovascular network. In 12 eyes incipient fibrosis had developed in the exudative lesion.

Yellow dye laser radiation was used for laser thermotherapy because at its wavelength of 578 nm absorption by oxyhaemoglobin is maximal. Treatment parameters were comparable to those of transpupillary LTT of choroidal melanomas—namely, a long exposure time (2 or 5 seconds), a low power setting (100–200 mW), and a large diameter of the laser beam (750 or 1000 µm). Treatment was performed over the entire lesion with a pattern of multiple confluent applications, mean number 11 (range 4–20), with the exclusion of the area of subfoveally located newly formed vessels. A rather low energy level of the laser was used initially, which did not cause an ophthalmoscopically visible effect. The energy level was then increased stepwise until a slightly greyish discoloration of the CNV complex developed at the end of the exposure time. A white coagulation effect was intentionally avoided. The difference between a photoocoagulation spot in the macula and a thermotherapeutic lesion just after delivery is shown in Figure 1. The follow up after LTT was 4–16 months, with a mean of 5 months.

Treatment results were evaluated by ophthalmoscopic, photographic, and fluorescein angiographic examination at 4, 6, 9, and 16 weeks after LTT, and thereafter every 3 months.
Table 1  Yellow dye laser thermotherapy (LTT) of CNV in AMD. Clinical data and results of LTT in 24 patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Visual symptoms (weeks)</th>
<th>Area of CNV (DA)</th>
<th>CNV details</th>
<th>Haem fibrosis</th>
<th>Result LTT ≥ 6 weeks</th>
<th>Choroidal perfusion</th>
<th>Result LTT 4 months</th>
<th>Visual acuity pre-LTT</th>
<th>Visual acuity post-LTT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>3</td>
<td>S/C</td>
<td>—</td>
<td>+</td>
<td>+</td>
<td>1.60</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>1</td>
<td>S/C</td>
<td>H</td>
<td>—</td>
<td>—</td>
<td>O</td>
<td>0.1</td>
<td>0.08</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>1</td>
<td>C</td>
<td>—</td>
<td>+</td>
<td>—</td>
<td>0.2</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>2</td>
<td>C</td>
<td>—</td>
<td>+</td>
<td>—</td>
<td>0.25</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>1</td>
<td>C</td>
<td>H</td>
<td>—</td>
<td>—</td>
<td>O</td>
<td>0.08</td>
<td>1/60</td>
</tr>
<tr>
<td>6</td>
<td>10</td>
<td>2</td>
<td>C</td>
<td>F</td>
<td>—</td>
<td>+</td>
<td>1.60</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>3</td>
<td>C</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>3</td>
<td>S/O</td>
<td>H/F</td>
<td>+</td>
<td>+</td>
<td>0.16</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>3</td>
<td>S/C</td>
<td>H/F</td>
<td>—</td>
<td>—</td>
<td>0.12</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>3</td>
<td>S/C</td>
<td>H/F</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.12</td>
<td>=</td>
</tr>
<tr>
<td>11</td>
<td>10</td>
<td>1</td>
<td>S/C</td>
<td>+</td>
<td>+</td>
<td>R</td>
<td>1/60</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>8</td>
<td>2</td>
<td>S/C</td>
<td>H</td>
<td>+</td>
<td>+</td>
<td>0.16</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>4</td>
<td>1</td>
<td>S/C</td>
<td>H</td>
<td>—</td>
<td>—</td>
<td>0.08</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>20</td>
<td>4</td>
<td>S/C</td>
<td>H/F</td>
<td>—</td>
<td>—</td>
<td>0.16</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>16</td>
<td>5</td>
<td>S/C</td>
<td>F</td>
<td>+</td>
<td>—</td>
<td>1.60</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>3</td>
<td>1</td>
<td>C</td>
<td>H</td>
<td>+</td>
<td>+</td>
<td>0.1</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>12</td>
<td>2</td>
<td>S/C</td>
<td>H/F</td>
<td>—</td>
<td>+</td>
<td>0.16</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>16</td>
<td>1</td>
<td>O</td>
<td>H/F</td>
<td>+</td>
<td>R</td>
<td>0.08</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>6</td>
<td>2</td>
<td>O</td>
<td>HEF</td>
<td>—</td>
<td>—</td>
<td>0.08</td>
<td>1/60</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>16</td>
<td>4</td>
<td>S/C</td>
<td>H/F</td>
<td>—</td>
<td>+</td>
<td>1/60</td>
<td>1/300</td>
<td>—</td>
</tr>
<tr>
<td>21</td>
<td>18</td>
<td>4</td>
<td>S/C</td>
<td>H/F</td>
<td>—</td>
<td>—</td>
<td>no effect</td>
<td>1/60</td>
<td>—</td>
</tr>
<tr>
<td>22</td>
<td>20</td>
<td>2</td>
<td>S/C</td>
<td>HEF</td>
<td>+</td>
<td>+</td>
<td>1.60</td>
<td>=</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>8</td>
<td>1</td>
<td>C</td>
<td>—</td>
<td>—</td>
<td>P</td>
<td>0.4</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>5</td>
<td>1</td>
<td>C</td>
<td>H</td>
<td>—</td>
<td>P</td>
<td>0.3</td>
<td>0.2</td>
<td></td>
</tr>
</tbody>
</table>

Patients in alphabetic sequence. DA = disc area; CNV details: S = CNV also subfoveally located; C = classic CNV; O = CNV partly occult; H = haemorrhage partly obscuring the CNV; F= subretinal fibrosis Results LTT ≥6 weeks (column 6) + = total disappearance of CNV on fluorescein angiogram. Choroidal perfusion (column 7) + = presence of choriocapillaris perfusion. Results LTT 4 months (column 8) ++++ = no recurrence of CNV. R = recurrence after 2 months of total regression CNV. O = outgrowth CNV within 6 weeks. P = partial regression of CNV. Visual acuity post treatment (column 10): = means unchanged visual acuity.

The outcome was classified as favourable when the CNV had totally regressed on fluorescein angiographic examination and remained so for minimally 6 weeks. Results were classified as unfavourable when there was incomplete destruction of the CNV or when neovascular outgrowth developed within 6 weeks after initially complete angiographic regression of the CNV.

Results

Treatment results are summarised in Tables 1 and 2. In 15 of 24 eyes (62.5%) LTT resulted in complete occlusion of the CNV on fluorescein angiography 4 weeks after LTT as evidenced by lack of hyperfluorescence and leakage from the neovascular network, also in the late phase. In three of the 15 successfully treated eyes (20%) neovascular outgrowth developed 4–6 weeks after LTT. In another three successfully treated eyes (20%) CNV recurred 2–4 months after LTT (Fig 5). Thus, in nine of the 15 initially successfully treated eyes (60%) the neovascular network regressed without recurrence. In six of these nine eyes the LTT induced effect was remarkably mild, because apart from regression of the exudative lesion, slight chorioretinal atrophy, and some hyperpigmentation in the treated area were the only ophthalmoscopic findings (Figs 2, 3). Regression of the CNV was not associated with the development of subretinal fibrosis. In four successfully treated eyes, chorioretinal fibrosis was already present before LTT but did not progress after treatment. Atrophic scar formation occurred in the treatment area in three eyes and resulted in chorioretinal atrophy 4–6 months after LTT. This did not cause loss of visual acuity because in these cases LTT was not performed in the foveal area (Fig 4).

Perfusion of the large choroidal vessels and choriocapillaris was seen on fluorescein angiograms in nine of the 12 favourably (>6 weeks) responding eyes (Fig 3C). In the other three eyes the choriocapillaris became occluded but non-leaking large choroidal vessels remained perfused. The perifoveal retinal capillary network remained perfused after treatment (Fig 3B, 5B).

LTT treatment failed in 12 eyes: in four destruction of the CNV was incomplete, in five LTT had no visible effect on the CNV, and in three there was early neovascular outgrowth. Retreatment with LTT was not done in this
pilot study. Haemorrhages or other treatment related complications were not observed during or after LTT.

The majority of patients (66%) had considerable loss of central vision (visual acuity 0.1 or less) before treatment. After LTT visual acuity remained unchanged in 17 eyes, it decreased in six, and increased in one eye. In the nine successfully treated eyes the visual acuity remained unchanged (Table 1).

Discussion

In this pilot study we investigated the potential of LTT as a new treatment for CNV in exudative AMD. Heat at a subcoagulation temperature in LTT occluded the CNV in 15 eyes (62.5%). Four months after treatment CNV remained eradicated in nine eyes (37.5%), as evidenced by fluorescein angiography. Neovascular outgrowth within 6 weeks after LTT was observed in three eyes. We classified these results as failures because the outgrowth in this short post-treatment period possibly originated from the CNV, which was not completely occluded by LTT but failed to show perfusion on the first fluorescein angiogram after LTT. Recurrences were observed in three eyes, 2–4 months after LTT.

The ophthalmoscopic results 4 months after LTT were variable, ranging from no visible effect in six eyes to the development of a mild atrophic chorioretinal scar in the treated area in three eyes. This variability was not related to the power setting of the laser or to the exposure time. It was unexpected because in all patients the end point of LTT was the development of a slight greyish discoloration of the fundus in the target area, which was the parameter for treatment intensity. This discoloration has proved to be a useful yardstick for the energy level to be used in transpupillary thermotherapy of choroidal melanomas. The difference in the effect of thermotherapy may be related to a large variation in the heat sensitivity of the retina. In rabbits clinically barely detectable diode laser lesions of the retina were associated with a variable tissue response in the microscopic specimens. The same results were obtained for eyes treated for 2 or 5 seconds. In addition, LTT treatment outcome did not depend on the duration of visual complaints, or on the size or localisation of the CNV and the presence of haemorrhages or fibrosis in the exudative lesion.

In all eyes which responded favourably to treatment the ophthalmoscopic and fluorescein angiographic damage to the retina and choroid was less after LTT than after photocoagulation treatment. In six eyes discrete pigmentary changes with slight chorioretinal atrophy in the treated area were the only fundusoscopic findings after LTT (Figs 2 and 3).

A perfusion defect in the choriocapillaris could account for the pathological changes in AMD because the choriocapillaris supplies the retinal pigment epithelium and outer retina. Ischaemia and hypoxia may trigger the development of new vessels, mediated by the vascular endothelial growth factor. There is considerable evidence of decreased choroidal perfusion in patients with AMD and a prolonged choriocapillaris filling time on angiography in patients with neovascular AMD.

For LTT we selected the power, spot size, exposure time, and wavelength so as to cause occlusion of newly formed vessels without interfering with the choroidal and retinal circulation. This is important because choroidal perfusion is essential for the function of the outer retinal layer and the retinal pigment epithelial layer. In 12 eyes with a favourable result after LTT it was possible to evaluate the choroidal circulation, which remained perfused in nine eyes (75%); in two eyes the choriocapillaris became occluded but large choroidal vessels remained perfused, and in one eye it was difficult to evaluate. In all eyes
the retinal vasculature was not damaged and perfusion was unchanged after LTT, indicating that heat was mainly produced at the CNV as target and was not conducted into the retina. The selective occlusion of the newly formed vessels can be explained by their increased vulnerability to heat compared with the normal vasculature. In addition, dissipation of heat by the choroid is very efficient because the fast circulation in its dense vascular network has a strong cooling effect. Even though choroidal perfusion persisted after LTT, recurrence of CNV was observed in three of 12 eyes after initially successful treatment. However, the presence of choriocapillaris perfusion does not provide any quantitative data on blood flow. LTT did not cause the formation of fibrotic scars and the fibrotic component of fibrovascular lesions did not increase after LTT. Hyperthermia has even been shown to exert a mitigating effect on proliferating processes.

LTT was performed mainly in patients with a rather poor prognosis by conventional photocoagulation treatment. Nineteen had one or more unfavourable AMD related findings which made them poorly eligible for photocoagulation treatment, such as the presence of blood obscuring the borders of the CNV.

![Figure 3](image1.png)

**Figure 3** (A) Fluorescein angiogram of the fundus of patient 1, showing a partly subfoveally situated CNV extending superiorly and nasally. (B) The angiogram 9 weeks after LTT shows total occlusion of CNV, filling of the choroidal arteries in the treated area, and normal retinal vasculature. (C) Late phase angiography of the treated area shows diffuse fluorescence and hyperfluorescence in the foveal area 16 weeks after LTT. There are no signs of leakage. (D) Fundus appearance 6 months after LTT showing discrete pigmentary changes in the treated area, without fibrotic scar formation. In spite of the same power setting the outer zone of the treated area had a more atrophic appearance than the central treated area.

![Figure 4](image2.png)

**Figure 4** (A) Fundus of patient 8 with a haemorrhagic AMD, directly after LTT treatment of the CNV in the macular area. The effect of thermotherapy is seen as a just visible slightly greyish haze. (B) In 16 months after LTT the macula became atrophic, except the untreated foveal area; visual acuity remained unchanged at 0.16.
Other treatments, aiming at selective occlusion of CNV with minimal damage to the sensory retina and preservation of visual acuity have been introduced. The results of ionising radiation therapy of CNV in AMD are controversial. Photodynamic therapy with verteporfin as photosensitiser has shown promising results. In patients with classic CNV there was less than a 15 letter loss of visual acuity in 67% in the treated eyes versus 39% in the control group. As recurrences develop frequently, most patients require multiple treatments, on average 3.7 in the first year, with this expensive drug.

The results of our pilot study show that CNV in AMD can effectively be occluded by transpupillary yellow dye LTT. With this technique light is converted into heat, preferentially at the CNV, thereby sparing the retinal and to some extent also the choroidal circulation. Unfortunately, the effect of LTT is rather unpredictable and the persistence of choroidal perfusion did not prevent the development of recurrences. When further developed, yellow dye LTT may become a useful option for treating CNV in AMD.


